Small Cap Feast
Small Cap Feast – 09 October 2020
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Meritwell II intends to list on the Specialist Funds Segment of the LSE raising up to £250m. The Placing will provide UK institutions with the opportunity to “swap” illiquid holdings which have become time and resource consuming holdings, at their bid price, in return for ordinary shares in the Company. Due 26 Oct.
YAMANA GOLD INC. (TSX:YRI; NYSE:AUY, LSE:AUY) to join the Main Market (standard). It is already listed on the TSX and NYSE. Yamana offers “investors exposure to a pure-play senior gold producer with a high-quality asset portfolio in mining-friendly jurisdictions in the Americas “ Due 13 October. Mkt cap US$5.27bn.
Mailbox REIT PLC , a newly formed single asset company which owns the Mailbox , a large prime office-led mixed use property in Birmingham which has been independently valued at £179m, announced its intention to raise up to £62.5m MailBox REIT will apply for the Ordinary Shares be admitted to trading on the IPSX Prime segment of International Property Securities Exchange (IPSX ). IPSX is a new Regulated Investment Exchange regulated by the FCA and is the world’s first such exchange dedicated to the initial public offering and secondary market trading of companies owning single institutional grade real estate assets and multiple assets with commonality. Due 21 October.
AIM Schedule One from Fonix, a mobile payments and messaging Company, enabling businesses to charge users’ mobile bills and send users SMSs via their Carrier. Due 12 October. £45m secondary placing. Anticipated mkt cap £90m.
Kaspi.kz, which operates the Kaspi.kz Super App, Kazakhstan’s most popular mobile app and the gateway to its market leading Payments, Marketplace and Fintech platforms intends to conduct a secondary GDR offer on the LSE. Timing tbc
Tirupati Graphite, the fully-integrated, cash generative, specialist graphite and graphene producer with operations in Madagascar and India, announced its potential intention to undertake an initial public offering on the LSE (standard listing). Timing tbc
Buffettology Smaller Companies Investment Trust— Buffettology is seeking to raise a minimum of £100m via an initial placing, an offer for subscription and an intermediaries offer on the Main Market. will be the Investment Manager to the Company, led by Keith Ashworth-Lord (CIO of Sanford Deland Asset Management Limited). Sanford DeLand manages approximately £1.4bn across two open ended funds, the CFP SDL UK Buffettology Fund and the Free Spirit® Fund. Due 29 October.
Wheaton precious Metals (TSE:WPM) – Proposed secondary listing on bringing one of the world’s largest precious metal streaming companies to the London Stock Exchange. Due Q4 2020.
HOME REIT intends to float to the Main Market and has confirmed a raise of £24o.6m at 100p. The Company will seek to contribute to the alleviation of homelessness in the UK, whilst targeting inflation-protected income and capital returns, by investing in a diversified portfolio of assets across the UK which will be dedicated to providing accommodation to the homeless. Due 12 October.
Umuthi Healthcare Solutions Plc, the technology led healthcare business focused on the distribution of pharmaceuticals and the provision of medical facilities in remote areas, seeking admission to the Standard Listing segment of the Official List. Timing tbc
Kibo Energy PLC, the multi-asset Africa focused energy Company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (MED), to the Standard List of the London Stock Exchange plc. Targeted for Q4 2020. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets, exploiting a growth niche market in the UK for Reserve Power generation to balance out the national grid at critical times.
Titon Holdings 86p £9.6m (TON.L)
The international manufacturer and supplier of ventilation systems, and window and door hardware, announced an update on trading for the year ended 30 September 2020. Full year results are expected to be announced on 14 January 2021.
Strong fourth quarter recovery after March manufacturing suspension
The Group expects revenues for the 12 months ended 30 September 2020 to be in the region of £21m, a decline of approximately 23% compared to the year to 30 September 2019. As announced earlier this year, sales in the period in the UK, Europe and South Korea were significantly impacted by the COVID-19 pandemic and the associated disruption to production and trading. However, trading has recovered ahead of the Board’s expectations, particularly in the quarter ended September 2020.
Minds & Machines 5.775p £52.1m (MMX.L)
The Board is commencing a formal investigation to determine whether certain revenue has been correctly recognized. The investigation will focus principally on a specific contract with multiple elements that was entered into in 2019 and relates to whether all requirements for the recognition of revenue had been met prior to 31 December 2019 and 30 June 2020 or whether such amounts should have been classified as a refundable deposit against future sales or deferred revenue at those dates.
Cash of $1.125m has been received in connection with the relevant contract and revenue of $938,000 was recognised in the year ended 31 December 2019 and $25,000 in the 6 months ended 30 June 2020.
The Board emphasizes that the investigation relates to revenue recognition and the Board does not expect it to have any impact on cash save for a maximum exposure of approximately $1.0m if the amounts received under the contract were to be refundable and no further revenue was generated. The Company had cash of $7.3m at 30 June 2020.
Diurnal Group 62.5p £76.26m (DNL.L)
The specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces a proposed conditional placing with institutional investors to raise up to approximately £8.0 million in aggregate before expenses at the Issue Price of 60 pence per Placing Share and an Open Offer to raise up to a further £2.0 million. Funds raised will be used primarily to support the continued development of the Company’s third product, DITEST™ as well as commencing Phase III preparation activities for Chronocort® in the US and progressing the Group’s early-stage pipeline.
Phoenix Global Resources 7.325p £204.12m (PGR.L)
HY June 20 Results. · Average daily production of 4,369 boepd (H1 2019: 9,630 boepd)
- Majority of production shut-in with effect from April. · Significant cost reductions have and continue to be implemented. · Phased restart of production during Q3 including at its operated licences Puesto Rojas, Tupungato and Atamisqui and its non-operated licences Chachahuen.
2020 interim results summary
- Revenues of US$24.9 million (H1 2019: US$68.6 million). · Realised oil price of US$39.19/bbl (H1 2019: US$52.23/bbl)
- Operating loss of US$ 50.8 million (H1 2019: loss of US$ 32.9 million)
Whilst the environment continues to be extremely challenging, the Company has taken significant steps to, and continues to, reduce its costs in all areas of the business. The Board believes this will put the Company in a stronger position to produce oil economically at lower prices with a positive contribution to cash flow and allow it to focus on the continued development of its unconventional assets.
The Company’s major shareholder, Mercuria, continues to be supportive and the Board, whilst exercising a degree of caution, believes the actions being taken will put the Company on a sounder financial footing, whilst appreciating this position could change very quickly in these uncertain times.
Dekel Agri-Vision 2.65p £11.24m (DKL.L)
Production update for its vertically integrated palm oil project at Ayenouan in Côte d’Ivoire for September 2020 and also for the three month period ended 30 September 2020.
Crude palm oil (‘CPO’) production at the Company’s mill at Ayenouan increased 54% to 1,965 tonnes in September 2020 compared to the 1,274 tonnes produced in September 2019. Following September’s strong performance, Q3 2020 saw 5,280 tonnes of CPO produced at Ayenouan, a 10% increase on Q3 2019’s 4,803 tonnes. In addition, September 2020 saw a continuation of the recent trend of improved global CPO pricing and higher extraction rates with CPO prices up 38% to €604 per tonne (Sept 2019: €438 per tonne) and extraction rates up to 21.2% (Sept 2019: 18.7%). As a result, the Company’s H2 2020 results remain on course to post a material improvement on H2 2019.
RUA Life Sciences 152p £24.26m (RUA.L)
The holding company of a group of medical device businesses focused on the exploitation of the world’s leading long-term implantable biostable polymer (Elast-Eon ™ ), is pleased to announce that its subsidiary RUA Vascular, which is developing Elast-Eon ™ sealed vascular grafts and cardiac/vascular patches, has made further progress on both the regulatory and commercial pathways towards product launch.
As previously announced on 5 August 2020, RUA Vascular recently reached the important milestone of achieving design freeze on its vascular graft products. This allowed grafts to enter the regulatory testing phase in advance of 510k submission to the FDA.
Good progress has also been made on commercialising the product development work successfully undertaken by the Company’s R&D team. The route to market is anticipated to be through a combination of Original Equipment Manufacturer (OEM) agreements and distribution agreements. RUA has been engaged with the medical device industry for some time with regards to potential OEM agreements. These discussions are developing at pace and have now progressed to sharing volume data and requests for quotations.
Alien Metals 0.76p £23m (UFO.L)
The Company’s technical team has successfully completed the follow-up detailed geological mapping and sampling programme at the Company’s Hamersley Iron Ore Projects.
– Detailed geological mapping and sampling completed over four of the five priority prospects targeted as part of the site visit
o Field observations indicate that the BHP 19 and BHP 20 prospects may be part of same larger system
o Additional prospective iron ore units mapped at the Brockman Iron project
– Programme has been successful in validating previously announced Maiden Exploration Targets across both projects
– 95 samples were taken across the projects, with assay results expected late October 2020
– Final results from sample assays and detailed mapping to assist with preparation of maiden drilling campaign
Immunodiagnostic Systems 240p £69.1m (IDH.L)
Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 13 August, its fully automated SARS-CoV-2 IgM antibody test (“the Test”) will be available for sale from today.
The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. We have commenced the process of working with various national reference centres and governmental bodies to ensure a roll-out according to national guidelines.
Ovoca Bio 9.75p £8m (OVB.L)
Ovoca Bio, a biopharmaceutical company with a focus on women’s health, announced the appointment of Christopher Wiltshire as Chief Business Officer and Executive Director of the Board, effective immediately. Mr. Wiltshire previously served as Non-Executive Director of the Board of Ovoca Bio.
Mr. Wiltshire is an experienced senior pharmaceutical and biotechnology executive with over 25 years of international experience. He currently serves as the Chief Executive of Hematherix LLC which is developing a recombinant clotting factor, and is former head of Business Development and Licensing at La Jolla Pharmaceutical (NASDAQ). He has a successful consultancy practice which provides strategic advice to early and mid-stage biotechnology and pharmaceutical companies. Mr. Wiltshire previously served in a number of senior positions at Pfizer, including as Head of Business Transactions and Investments within The Pfizer Incubator LLC.
Aquila Services Group 26p £10.36m (AQSG.L)
Aquila, the quoted parent company of three main trading subsidiaries which provide professional consultancy and support services to organisations and businesses involved in the affordable housing, education, sports and community services sectors, announces that it has sold its 25% shareholding in 3C Consultants Ltd, a company providing IT consultancy services to the housing sector, (“3C”) under a share buyback arrangement. 3C have paid a cash consideration equivalent to Aquila’s original cost of investment of £219,345 plus 15%.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.